{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:26Z","timestamp":1786979966088,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06078-4","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T04:14:33Z","timestamp":1770005673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The characteristics of giant cell arteritis patients that went blind in spite of treatment: case based narrative literature review"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-8768","authenticated-orcid":false,"given":"Marcin","family":"Milchert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-4996","authenticated-orcid":false,"given":"Aleksandra","family":"Adamska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-4367","authenticated-orcid":false,"given":"Marek","family":"Brzosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"6078_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/md.0b013e31803d1764","volume":"86","author":"MA Gonzalez-Gay","year":"2007","unstructured":"Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ et al (2007) Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 86:61\u201368. https:\/\/doi.org\/10.1097\/md.0b013e31803d1764","journal-title":"Medicine (Baltimore)"},{"key":"6078_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.6061\/clinics\/2013(03)oa06","volume":"68","author":"AW Souza","year":"2013","unstructured":"Souza AW, Okamoto KY, Abrantes F, Schau B, Bacchiega AB, Shinjo SK (2013) Giant cell arteritis: a multicenter observational study in Brazil. Clin (Sao Paulo) 68:317\u2013322. https:\/\/doi.org\/10.6061\/clinics\/2013(03)oa06","journal-title":"Clin (Sao Paulo)"},{"key":"6078_CR3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0161-6420(82)34666-7","volume":"89","author":"JL Keltner","year":"1982","unstructured":"Keltner JL (1982) Giant-cell arteritis. Ophthalmology 89:1101\u20131110. https:\/\/doi.org\/10.1016\/S0161-6420(82)34666-7","journal-title":"Ophthalmology"},{"key":"6078_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0161-6420(93)31608-8","volume":"100","author":"PD Aiello","year":"1993","unstructured":"Aiello PD, Trautmann JC, McPhee TJ et al (1993) Visual prognosis in giant cell arteritis. Ophthalmology 100:550\u2013555. https:\/\/doi.org\/10.1016\/S0161-6420(93)31608-8","journal-title":"Ophthalmology"},{"key":"6078_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/rheumatology\/keu433","volume":"54","author":"SP Mollan","year":"2015","unstructured":"Mollan SP, Begaj I, Mackie S et al (2015) Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002-13, without a decrease in associated sight loss: potential implications for service provision. Rheumatology 54:375\u2013377. https:\/\/doi.org\/10.1093\/rheumatology\/keu433","journal-title":"Rheumatology"},{"key":"6078_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000070631","volume":"217","author":"SS Hayreh","year":"2003","unstructured":"Hayreh SS, Zimmerman B (2003) Management of giant cell arteritis. Ophthalmologica 217:239\u2013259. https:\/\/doi.org\/10.1159\/000070631","journal-title":"Ophthalmologica"},{"key":"6078_CR7","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00296-019-04422-5","volume":"39","author":"CS Chean","year":"2019","unstructured":"Chean CS, Prior JA, Helliwell T et al (2019) Characteristics of patients with giant cell arteritis who experience visual symptoms. Rheumatol Int 39:1789\u20131796. https:\/\/doi.org\/10.1007\/s00296-019-04422-5","journal-title":"Rheumatol Int"},{"key":"6078_CR8","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0161-6420(97)30222-X","volume":"104","author":"WT Cornblath","year":"1997","unstructured":"Cornblath WT, Eggenberger ER (1997) Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 104:854\u2013858. https:\/\/doi.org\/10.1016\/S0161-6420(97)30222-X","journal-title":"Ophthalmology"},{"key":"6078_CR9","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A et al (2021) 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol 73:1349\u20131365. https:\/\/doi.org\/10.1002\/art.41774","journal-title":"Arthritis Rheumatol"},{"key":"6078_CR10","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","volume":"392","author":"D Blockmans","year":"2025","unstructured":"Blockmans D, Penn SK, Setty AR et al (2025) A phase 3 trial of upadacitinib for giant-cell arteritis. N Engl J Med 392:2013\u20132024. https:\/\/doi.org\/10.1056\/NEJMoa2413449","journal-title":"N Engl J Med"},{"key":"6078_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-025-05796-5","volume":"45","author":"T Ito","year":"2025","unstructured":"Ito T, Fukui S, Nagase FN et al (2025) A feasible treatment strategy for tapering subcutaneous tocilizumab in giant cell arteritis: a 24-month multi-center retrospective study. Rheumatol Int 45:45. https:\/\/doi.org\/10.1007\/s00296-025-05796-5","journal-title":"Rheumatol Int"},{"key":"6078_CR12","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"6078_CR13","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e225","volume":"39","author":"IC Benlidayi","year":"2024","unstructured":"Benlidayi IC, Gupta L (2024) CAse-BAsed REview sTandards (CABARET): considerations for authors, reviewers, and editors. J Korean Med Sci 39:e225. https:\/\/doi.org\/10.3346\/jkms.2024.39.e225","journal-title":"J Korean Med Sci"},{"key":"6078_CR14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122\u20131128. https:\/\/doi.org\/10.1002\/art.1780330810","journal-title":"Arthritis Rheum"},{"key":"6078_CR15","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/art.42325","volume":"74","author":"C Ponte","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC et al (2022) 2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis. Arthritis Rheumatol 74:1881\u20131889. https:\/\/doi.org\/10.1002\/art.42325","journal-title":"Arthritis Rheumatol"},{"key":"6078_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-025-05965-6","volume":"45","author":"R Bergner","year":"2025","unstructured":"Bergner R, L\u00f6ffler C, Schulz P et al (2025) New versus old: comparison of the 2022 ACR\/EULAR versus the 1990 ACR classification criteria for giant cell arteritis in a real-world cohort. Rheumatol Int 45:248. https:\/\/doi.org\/10.1007\/s00296-025-05965-6","journal-title":"Rheumatol Int"},{"key":"6078_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/ard-2023-223895","volume":"82","author":"S Monti","year":"2023","unstructured":"Monti S, Milanesi A, Klersy C et al (2023) Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients. Ann Rheum Dis 82:1098\u20131106. https:\/\/doi.org\/10.1136\/ard-2023-223895","journal-title":"Ann Rheum Dis"},{"key":"6078_CR18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/jnnp.2006.113787","volume":"78","author":"T Loddenkemper","year":"2007","unstructured":"Loddenkemper T, Sharma P, Katzan I, Plant GT (2007) Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry 78:1255\u20131259. https:\/\/doi.org\/10.1136\/jnnp.2006.113787","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6078_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-228251","volume":"12","author":"A Le Goueff","year":"2019","unstructured":"Le Goueff A, Peters J, Willcocks L, Jayne D (2019) Visual loss in giant cell arteritis 3 weeks after steroid initiation. BMJ Case Rep 12:e228251. https:\/\/doi.org\/10.1136\/bcr-2018-228251","journal-title":"BMJ Case Rep"},{"key":"6078_CR20","first-page":"57","volume":"53","author":"E \u00dcnald\u0131","year":"2022","unstructured":"\u00dcnald\u0131 E (2022) A case of giant cell arteritis with anterior ischemic optic neuropathy resistant to corticosteroid therapy. Acta Med 53:57\u201358","journal-title":"Acta Med"},{"key":"6078_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.semarthrit.2019.02.011","volume":"49","author":"E Liozon","year":"2019","unstructured":"Liozon E, Delmas C, Dumonteil S et al (2019) Features and prognosis of giant cell arteritis in patients over 85 years of age: a case-control study. Semin Arthritis Rheum 49:288\u2013295. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.011","journal-title":"Semin Arthritis Rheum"},{"key":"6078_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew397","author":"M Yates","year":"2016","unstructured":"Yates M, MacGregor AJ, Robson J et al (2016) The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kew397","journal-title":"Rheumatology"},{"key":"6078_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02480-4","volume":"23","author":"J Amsler","year":"2021","unstructured":"Amsler J, Kysela I, Tappeiner C et al (2021) Vision loss in patients with giant cell arteritis treated with tocilizumab. Arthritis Res Ther 23:92. https:\/\/doi.org\/10.1186\/s13075-021-02480-4","journal-title":"Arthritis Res Ther"},{"key":"6078_CR24","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3899\/jrheum.090269","volume":"36","author":"TA Kermani","year":"2009","unstructured":"Kermani TA, Matteson EL, Hunder GG, Warrington KJ (2009) Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol 36:2277\u20132283. https:\/\/doi.org\/10.3899\/jrheum.090269","journal-title":"J Rheumatol"},{"key":"6078_CR25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/1756-185X.12631","volume":"19","author":"P Ungprasert","year":"2016","unstructured":"Ungprasert P, Thongprayoon C, Kittanamongkolchai W et al (2016) Peripheral arterial disease in patients with giant cell arteritis: a meta-analysis. Int J Rheum Dis 19:819\u2013825. https:\/\/doi.org\/10.1111\/1756-185X.12631","journal-title":"Int J Rheum Dis"},{"key":"6078_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","volume":"48","author":"C Salvarani","year":"2008","unstructured":"Salvarani C, Bella CD, Cimino L et al (2008) Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology 48:250\u2013253. https:\/\/doi.org\/10.1093\/rheumatology\/ken465","journal-title":"Rheumatology"},{"key":"6078_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0871-z","volume":"15","author":"JA Prior","year":"2017","unstructured":"Prior JA, Ranjbar H, Belcher J et al (2017) Diagnostic delay for giant cell arteritis \u2013 a systematic review and meta-analysis. BMC Med 15:120. https:\/\/doi.org\/10.1186\/s12916-017-0871-z","journal-title":"BMC Med"},{"key":"6078_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1442-9071.2004.00826.x","volume":"32","author":"B Zborowska","year":"2004","unstructured":"Zborowska B, Ell J, McGee-Collett M et al (2004) Progressive visual loss in a patient with presumed temporal arteritis despite treatment: how to make the diagnosis. Clin Exp Ophthalmol 32:335\u2013336. https:\/\/doi.org\/10.1111\/j.1442-9071.2004.00826.x","journal-title":"Clin Exp Ophthalmol"},{"key":"6078_CR29","doi-asserted-by":"publisher","DOI":"10.56305\/001c.92898","author":"AT Barton","year":"2024","unstructured":"Barton AT, Francis ER, Feibelman P et al (2024) Recurrent vision loss in a patient with giant cell arteritis while on high dose corticosteroids. J Brown Hosp Med. https:\/\/doi.org\/10.56305\/001c.92898. 3:","journal-title":"J Brown Hosp Med"},{"key":"6078_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.22374\/cjgim.v12i3.159","volume":"12","author":"H Burton","year":"2017","unstructured":"Burton H, Farrell L, Atkins EJ (2017) Unexpected visual loss in appropriately treated giant cell arteritis. Can J Gen Intern Med 12:13\u201316. https:\/\/doi.org\/10.22374\/cjgim.v12i3.159","journal-title":"Can J Gen Intern Med"},{"key":"6078_CR31","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00296-022-05160-x","volume":"42","author":"IN Kokloni","year":"2022","unstructured":"Kokloni IN, Aligianni SI, Makri O, Daoussis D (2022) Vision loss in giant cell arteritis: case-based review. Rheumatol Int 42:1855\u20131862. https:\/\/doi.org\/10.1007\/s00296-022-05160-x","journal-title":"Rheumatol Int"},{"key":"6078_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0002-9394(98)00313-4","volume":"127","author":"J-M Hwang","year":"1999","unstructured":"Hwang J-M, Girkin CA, Perry JD et al (1999) Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite corticosteroid treatment. Am J Ophthalmol 127:102\u2013104. https:\/\/doi.org\/10.1016\/S0002-9394(98)00313-4","journal-title":"Am J Ophthalmol"},{"key":"6078_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1440725","volume":"11","author":"M Milchert","year":"2024","unstructured":"Milchert M, W\u00f3jcik K, Musia\u0142 J et al (2024) Increased interest with the introduction of fast-track diagnostic pathway is associated with the regionally increased frequency of giant cell arteritis in Poland: a study based on POLVAS registry data. Front Med 11:1440725. https:\/\/doi.org\/10.3389\/fmed.2024.1440725","journal-title":"Front Med"},{"key":"6078_CR34","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1177\/039463201002300433","volume":"23","author":"M Montalto","year":"2010","unstructured":"Montalto M, Biolato M, Gallo A et al (2010) Severe giant cell arteritis associated with essential thrombocythaemia. Int J Immunopathol Pharmacol 23:1271\u20131274. https:\/\/doi.org\/10.1177\/039463201002300433","journal-title":"Int J Immunopathol Pharmacol"},{"key":"6078_CR35","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.lpm.2019.07.031","volume":"48","author":"A R\u00e9gent","year":"2019","unstructured":"R\u00e9gent A, Ly KH, Mouthon L (2019) Physiopathologie de l\u2019art\u00e9rite \u00e0 cellules g\u00e9antes: de l\u2019inflammation Au remodelage vasculaire. La Presse Med 48:919\u2013930. https:\/\/doi.org\/10.1016\/j.lpm.2019.07.031","journal-title":"La Presse Med"},{"key":"6078_CR36","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3899\/jrheum.151033","volume":"43","author":"M Saleh","year":"2016","unstructured":"Saleh M, Turesson C, Englund M et al (2016) Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study. J Rheumatol 43:1559\u20131565. https:\/\/doi.org\/10.3899\/jrheum.151033","journal-title":"J Rheumatol"},{"key":"6078_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00296-025-05930-3","volume":"45","author":"CE Currier","year":"2025","unstructured":"Currier CE, Bays AM, Thomason JL (2025) Normal inflammatory markers in giant cell arteritis: a diagnostic blind spot. Rheumatol Int 45:175. https:\/\/doi.org\/10.1007\/s00296-025-05930-3","journal-title":"Rheumatol Int"},{"key":"6078_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/1179547619857690","volume":"12","author":"LC DeBord","year":"2019","unstructured":"DeBord LC, Chiu I, Liou NE (2019) Delayed diagnosis of giant cell arteritis in the setting of isolated lingual necrosis. Clin Med Insights Case Rep 12:1179547619857690. https:\/\/doi.org\/10.1177\/1179547619857690","journal-title":"Clin Med Insights Case Rep"},{"key":"6078_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00296-020-04730-1","volume":"41","author":"B Ince","year":"2021","unstructured":"Ince B, Artan S, Yalcinkaya Y et al (2021) Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage. Rheumatol Int 41:439\u2013448. https:\/\/doi.org\/10.1007\/s00296-020-04730-1","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06078-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:58:08Z","timestamp":1771646288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06078-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6078"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06078-4","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No financial or any other conflicts of interests regarding this paper were recognized for any of authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent for publication was obtained from both patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"37"}}